Showing results (301-310 of 618) with videos related to
Sort By:
Pageof 62
Journal of Neuro-Oncology|March 1, 2021
Clinical, radiological and genomic features and targeted therapy in BRAF V600E mutant adult glioblastomaMary Jane Lim-Fat, Kun Wei Song, J Bryan Iorgulescu, et al.Neuro-Oncology|March 8, 2011
A phase I/II trial of the histone deacetylase inhibitor romidepsin for adults with recurrent malignant glioma: North American Brain Tumor Consortium Study 03-03Fabio M Iwamoto, Kathleen R Lamborn, John G Kuhn, et al.Journal of Neuro-Oncology|November 30, 2018
Increase of pseudoprogression and other treatment related effects in low-grade glioma patients treated with proton radiation and temozolomideMichael Dworkin, William Mehan, Andrzej Niemierko, et al.The Oncologist|December 7, 2013
Low incidence of pseudoprogression by imaging in newly diagnosed glioblastoma patients treated with cediranib in combination with chemoradiationMarco C Pinho, Pavlina Polaskova, Jayashree Kalpathy-Cramer, et al.Expert Review of Vaccines|June 12, 2013
An update on vaccine therapy and other immunotherapeutic approaches for glioblastomaDavid A Reardon, Kai W Wucherpfennig, Gordon Freeman, et al.Breast Cancer Research and Treatment|October 5, 2024
Intracranial outcomes following neurosurgical resection in patients with brain metastases secondary to HER2-positive breast cancer versus other subtypesNarmeen S Rashid, Nayan Lamba, Paul J Catalano, et al.Cancer Discovery|May 17, 2012
Differential sensitivity of glioma- versus lung cancer-specific EGFR mutations to EGFR kinase inhibitorsIgor Vivanco, H Ian Robins, Daniel Rohle, et al.Journal of Neuro-Oncology|October 21, 2023
Activity of a first-in-class oral HIF2-alpha inhibitor, PT2385, in patients with first recurrence of glioblastomaRoy Strowd, Benjamin Ellingson, Catalina Raymond, et al.Journal of Neuro-Oncology|January 20, 2011
Lonafarnib (SCH66336) improves the activity of temozolomide and radiation for orthotopic malignant gliomasDeviney Chaponis, Jessica W Barnes, Jamie L Dellagatta, et al.Oncotarget|September 20, 2014
Combined VEGF and CXCR4 antagonism targets the GBM stem cell population and synergistically improves survival in an intracranial mouse model of glioblastomaAmy Barone, Rajarshi Sengupta, Nicole M Warrington, et al.Pageof 62